188 related articles for article (PubMed ID: 10780524)
41. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.
Pan LX; Chen ZP; Liu YS; Zhao JH
J Neurooncol; 2005 Aug; 74(1):71-6. PubMed ID: 16078111
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker.
Pizarro CB; Oliveira MC; Pereira-Lima JF; Leães CG; Kramer CK; Schuch T; Barbosa-Coutinho LM; Ferreira NP
Neuropathology; 2009 Feb; 29(1):40-4. PubMed ID: 18673444
[TBL] [Abstract][Full Text] [Related]
43. Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.
Ruggeri RM; Costa G; Simone A; Campennì A; Sindoni A; Ieni A; Cavallari V; Trimarchi F; Curtò L
J Endocrinol Invest; 2012 May; 35(5):473-8. PubMed ID: 21897111
[TBL] [Abstract][Full Text] [Related]
44. Correlation of bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia.
Saleh HA; Jackson H; Khatib G; Banerjee M
Pathol Oncol Res; 1999; 5(4):273-9. PubMed ID: 10607921
[TBL] [Abstract][Full Text] [Related]
45. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas.
de la Torre NG; Wass JA; Turner HE
Front Horm Res; 2004; 32():133-45. PubMed ID: 15281344
[TBL] [Abstract][Full Text] [Related]
46. Are markers of proliferation valuable in the histological assessment of pituitary tumours?
Turner HE; Wass JA
Pituitary; 1999 May; 1(3-4):147-51. PubMed ID: 11081192
[TBL] [Abstract][Full Text] [Related]
47. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas.
Jaffrain-Rea ML; Di Stefano D; Minniti G; Esposito V; Bultrini A; Ferretti E; Santoro A; Faticanti Scucchi L; Gulino A; Cantore G
Endocr Relat Cancer; 2002 Jun; 9(2):103-13. PubMed ID: 12121834
[TBL] [Abstract][Full Text] [Related]
48. Microvascular structural entropy: a novel approach to assess angiogenesis in pituitary tumors.
Vidal S; Horvath E; Kovacs K; Lloyd RV; Scheithauer BW
Endocr Pathol; 2003; 14(3):239-47. PubMed ID: 14586069
[TBL] [Abstract][Full Text] [Related]
49. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
50. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.
de la Torre NG; Turner HE; Wass JA
Pituitary; 2005; 8(1):17-23. PubMed ID: 16411064
[TBL] [Abstract][Full Text] [Related]
51. Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc.
Wang DG; Johnston CF; Atkinson AB; Heaney AP; Mirakhur M; Buchanan KD
J Clin Pathol; 1996 Oct; 49(10):795-7. PubMed ID: 8943742
[TBL] [Abstract][Full Text] [Related]
52. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
53. Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases.
Mahta A; Haghpanah V; Lashkari A; Heshmat R; Larijani B; Tavangar SM
Folia Neuropathol; 2007; 45(2):72-7. PubMed ID: 17594597
[TBL] [Abstract][Full Text] [Related]
54. MCM7 as a marker of postsurgical progression in non-functioning pituitary adenomas.
Hallén T; Olsson DS; Hammarstrand C; Örndal C; Engvall A; Ragnarsson O; Skoglund T; Johannsson G
Eur J Endocrinol; 2021 Apr; 184(4):521-531. PubMed ID: 33524001
[TBL] [Abstract][Full Text] [Related]
55. Interaction between morphology and angiogenesis in human early colorectal cancers.
Okada K; Satoh T; Fujimoto K; Tokunaga O
Pathol Int; 2004 Jul; 54(7):490-7. PubMed ID: 15189502
[TBL] [Abstract][Full Text] [Related]
56. Specific alterations of the basement membrane and stroma antigens in human pituitary tumours in comparison with the normal anterior pituitary. An immunocytochemical study.
Farnoud MR; Lissak B; Kujas M; Peillon F; Racadot J; Li JY
Virchows Arch A Pathol Anat Histopathol; 1992; 421(6):449-55. PubMed ID: 1281591
[TBL] [Abstract][Full Text] [Related]
57. Microvessel density and area in pituitary microadenomas.
Jasek E; Furgal-Borzych A; Lis GJ; Litwin JA; Rzepecka-Wozniak E; Trela F
Endocr Pathol; 2009; 20(4):221-6. PubMed ID: 19705298
[TBL] [Abstract][Full Text] [Related]
58. "Leiomyomatoid angiomatous neuroendocrine tumor" (LANT) of the pituitary reflects idiosyncratic angiogenesis in adenomas of the gonadotroph cell lineage.
Schürch C; Birrer M; Estella I; Kappeler A; Hewer E; Vajtai I
Pathol Res Pract; 2013 Mar; 209(3):155-60. PubMed ID: 23419690
[TBL] [Abstract][Full Text] [Related]
59. Haemorrhagic pituitary tumours.
Lazaro CM; Guo WY; Sami M; Hindmarsh T; Ericson K; Hulting AL; Wersäll J
Neuroradiology; 1994; 36(2):111-4. PubMed ID: 8183446
[TBL] [Abstract][Full Text] [Related]
60. Tumour vascularity and proliferation: clear evidence of a close relationship.
Weidner N
J Pathol; 1999 Nov; 189(3):297-9. PubMed ID: 10547589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
